These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 39206852)
1. Design, synthesis, and biological activity evaluation of dihydromyricetin derivatives against SARS-CoV-2-Omicron virus. Wu C; Jiang Q; Zhong H; Zhou X; Liu L; Pan T; Liu C; Wang W; Sheng W J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2390909. PubMed ID: 39206852 [TBL] [Abstract][Full Text] [Related]
2. Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis. Xiao T; Wei Y; Cui M; Li X; Ruan H; Zhang L; Bao J; Ren S; Gao D; Wang M; Sun R; Li M; Lin J; Li D; Yang C; Zhou H Phytomedicine; 2021 Oct; 91():153704. PubMed ID: 34419736 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CL Jiang Z; Feng B; Chen L; Nie T; Chen S; Wang L; Liu H; Yu T; Zhang Y; Zheng M; Xu Y; Liu H; Zang Y; Su H; Zhang L; Li J; Zhou Y J Med Chem; 2024 Aug; 67(15):12760-12783. PubMed ID: 39072488 [TBL] [Abstract][Full Text] [Related]
4. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors. Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513 [TBL] [Abstract][Full Text] [Related]
5. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470 [TBL] [Abstract][Full Text] [Related]
6. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors. Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337 [TBL] [Abstract][Full Text] [Related]
7. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317 [TBL] [Abstract][Full Text] [Related]
8. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL Du R; Cooper L; Chen Z; Lee H; Rong L; Cui Q Antiviral Res; 2021 Jun; 190():105075. PubMed ID: 33872675 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2. Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X Future Med Chem; 2024; 16(9):887-903. PubMed ID: 38618977 [TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. Dai W; Jochmans D; Xie H; Yang H; Li J; Su H; Chang D; Wang J; Peng J; Zhu L; Nian Y; Hilgenfeld R; Jiang H; Chen K; Zhang L; Xu Y; Neyts J; Liu H J Med Chem; 2022 Feb; 65(4):2794-2808. PubMed ID: 33872498 [TBL] [Abstract][Full Text] [Related]
11. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652 [TBL] [Abstract][Full Text] [Related]
12. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862 [TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies. Dampalla CS; Rathnayake AD; Perera KD; Jesri AM; Nguyen HN; Miller MJ; Thurman HA; Zheng J; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Kim Y; Groutas WC; Chang KO J Med Chem; 2021 Dec; 64(24):17846-17865. PubMed ID: 34865476 [TBL] [Abstract][Full Text] [Related]
14. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library. Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246 [TBL] [Abstract][Full Text] [Related]
15. Exploring of N-phthalimide-linked 1,2,3-triazole analogues with promising -anti-SARS-CoV-2 activity: synthesis, biological screening, and molecular modelling studies. Aljuhani A; Alsehli M; Seleem MA; Alraqa SY; Ahmed HEA; Rezki N; Aouad MR J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2351861. PubMed ID: 38847308 [TBL] [Abstract][Full Text] [Related]
16. Investigating the promising SARS-CoV-2 main protease inhibitory activity of secoiridoids isolated from Al-Karmalawy AA; Alnajjar R; Elmaaty AA; Binjubair FA; Al-Rashood ST; Mansour BS; Elkamhawy A; Eldehna WM; Mansour KA J Biomol Struct Dyn; 2024 Aug; 42(13):6941-6953. PubMed ID: 37505066 [TBL] [Abstract][Full Text] [Related]
17. Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2. Welker A; Kersten C; Müller C; Madhugiri R; Zimmer C; Müller P; Zimmermann R; Hammerschmidt S; Maus H; Ziebuhr J; Sotriffer C; Schirmeister T ChemMedChem; 2021 Jan; 16(2):340-354. PubMed ID: 32930481 [TBL] [Abstract][Full Text] [Related]
18. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease. Chaibi FZ; Brier L; Carré P; Landry V; Desmarets L; Tarricone A; Cantrelle FX; Moschidi D; Herledan A; Biela A; Bourgeois F; Ribes C; Ikherbane S; Malessan M; Dubuisson J; Belouzard S; Hanoulle X; Leroux F; Deprez B; Charton J Eur J Med Chem; 2024 Oct; 276():116707. PubMed ID: 39068863 [TBL] [Abstract][Full Text] [Related]
19. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*. Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984 [TBL] [Abstract][Full Text] [Related]
20. All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity. Morita T; Miyakawa K; Jeremiah SS; Yamaoka Y; Sada M; Kuniyoshi T; Yang J; Kimura H; Ryo A Viruses; 2021 Aug; 13(8):. PubMed ID: 34452533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]